	US 11,679,122 B2
	Therapeutic agent for nervous system disease
Hiroyuki Tanaka, Suita (JP); Hideki Yoshikawa, Suita (JP); Hideki Mochizuki, Suita (JP); Tsuyoshi Murase, Suita (JP); Tsutomu Sasaki, Suita (JP); Kousuke Baba, Suita (JP); Toru Iwahashi, Suita (JP); and Mitsuru Naiki, Kato (JP)
Assigned to OSAKA UNIVERSITY, Suita (JP); and NIPPON ZOKI PHARMACEUTICAL CO., LTD., Osaka (JP)
Filed by OSAKA UNIVERSITY, Suita (JP); and NIPPON ZOKI PHARMACEUTICAL CO., LTD., Osaka (JP)
Filed on May 19, 2022, as Appl. No. 17/748,553.
Application 17/748,553 is a division of application No. 16/907,913, filed on Jun. 22, 2020, granted, now 11,369,626.
Application 16/907,913 is a continuation of application No. PCT/JP2018/046945, filed on Dec. 20, 2018.
Claims priority of application No. JP2017-245133 (JP), filed on Dec. 21, 2017; and application No. JP2018-156503 (JP), filed on Aug. 23, 2018.
Prior Publication US 2022/0273692 A1, Sep. 1, 2022
Int. Cl. A61K 31/714 (2006.01); A61P 25/28 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/714 (2013.01) [A61K 9/0019 (2013.01); A61P 25/28 (2018.01)]

5 Claims

1. A method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method comprising administering an agent comprising an effective amount of vitamin B₁₂to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia.